BioCentury
ARTICLE | Company News

DRC approves compassionate use of investigational Ebola treatments

June 8, 2018 3:30 PM UTC

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access.

The World Health Organization said four of the five approved products are in the country: Zmapp from Mapp Biopharmaceutical Inc. (San Diego, Calif.); remdesivir (GS-5734) from Gilead Sciences Inc. (NASDAQ:GILD); REGN-EB3 (REGN3470-3471-3479) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); and mAb114 from Vir Biotechnology Inc. (San Francisco, Calif.)...